Etomidate

DB00292ApprovedInvestigationalSmall moleculeAnesthetics, General

Etomidate is a short-acting intravenous anesthetic indicated for the induction of anesthesia and supplementation of subpotent anesthesia during short operative procedures. Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system.

Mechanism: Etomidate binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
Curator reviewed
Primary indication: Used in the induction of general anesthesia.Curator reviewed · 1 structured indication
Formula / weight: C₁₄H₁₆N₂O₂ · 244.289 g/mol (avg)
First approval: Canada, 2020 · United States, 1996
Brand names: Amidate

Resolves to

Compound

UNIIZ22628B598CAS33125-97-2ChEMBLCHEMBL681ChEBI4910PubChem667484KEGGD00548

Clinical / RWD

RxNorm4177ATCN01AX07PharmGKBPA164743987

Structure

InChIKeyNPUKDXXFDDZOKR-LLVKDONJSA-NSMILESCCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1

Targets

P14867GABRA1P18089ADRA2BQ99928GABRG3

What you can answer from here — as of September 20, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1,603Drug interactionsStructured to mechanism, not free text

95Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

70Marketed productsAcross 8 countries and 40 labellers

1ATC codeIncluding every combination product, plus 14 drug categories

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with Etomidate, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In